参考文献/References:
[1] Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs[J]. Cell,1994,78(1):35-43.
[2] Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells[J].Circ Res, 1995,76(3):412-417.
[3] Nourse J, Firpo E, Flanagan WM,et al.Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin[J]. Nature,1994,372(6506):570-573.
[4] Schuler W, Sedrani R, Cottens S, et al.SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo[J]. Transplantation,1997,64(1):36-42.
[5] Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation(LEADERS): a randomised non-inferiority trial[J]. Lancet,2008,372(9644):1163-1173.
[6] Mullins DW,Walker TM,Burger CJ,et al.Taxol-mediated changes in fibrosarcoma-induced immune cell function:modulation of antitumor activities[J]. Cancer Immunol Immunother,1997,45(1):20-28.
[7] Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide[J]. J Immunol,1999,162(11):6811-6818.
[8] Shedden L,Oldroyd K, Connolly P. Current issues in coronary stent technology[J]. Proc Inst Mech Eng H,2009,223(5):515-524.
[9] Nakazawa G,Finn AV,Kolodgie FD, et al.A review of current devices and a look at new technology:drug-eluting stents[J]. Expert Rev Med Devices,2009,6(1):33-42.
[10] Murrell M, Khachigian L, Ward MR. The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting[J]. Atherosclerosis,2007,194(2):364-371.
[11] Santiago FS,Ishii H,Shafi S,et al. Yin Yang-1 inhibits intimal thickening by repressing p21WAF1/Cip1 transcription and p21WAF1/Cip1-Cdk4-Cyclin D1 assembly[J]. Circ Res,2007,101(2):146-155.
[12] Martin DM,Boyle FJ. Drug-eluting stents for coronary artery diease:a review[J].Med Eng Phys,2011,33(2):148-163.
[13] Leon MB,Nikolsky E,Cutlip DE, et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR Ⅳ trial[J]. J Am Coll Cardiol,2010,55(6):543-554.
[14] Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions(SPIRIT)Ⅲ trial[J]. Circulation,2009,119(5):680-686.
[15] Stone GW,Rizvi A,Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease[J]. N Engl J Med,2010,362(18):1663-1674.
[16] Kedhi E,Joesoef KS,McFadden E,et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice(COMPARE):a randomised trial[J]. Lancet,2010,375(9710):201-209.
[17] Serruys PW,Silber S,Garg S,et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents[J]. N Engl J Med,2010,363(2):136-146.
[18] John MC,Wessely R,Kastrati A,et al. Differential healing responses in polymer- and nonpolymer-based sirolimus-eluting stents[J]. JACC Cardiovasc Interv,2008,1(5):535-544.
[19] Swanson N,de Scheerder I,Chevalier B,et al.Two-year clinical results of a polymer-free,paclitaxel-eluting stent:the ELUTES trial[J]. EuroIntervention, 2007,3(1):109-112.
[20] Byrne RA,Lijima R,Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer[J]. JACC Cardiovasc Interv,2009,2(4):291-299.
[21] Mehilli J,Byrne RA,Wieczorek A,et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis[J]. Eur Heart J,2008,29(16):1975-1982.
[22] Byrne RA,Kastrati A,Kufner S, et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings:the Intracoronary Stenting and Angiographic Results:Test Efficacy of 3 Limus-Eluting Stents(ISAR-TEST-4)Trial[J]. Eur Heart J,2009,30(20):2441-2449.
[23] Colombo A, Sharp AS.The bioabsorbable stent as a virtual prosthesis[J]. Lancet,2009,373(9667):869-870.